ArticleClinical and translational radiation oncology2026
Oncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: In patients with biochemical recurrence (BCR) after radical prostatectomy (RP), prostate-specific membrane antigen (PSMA) PET/CT can detect early pelvic lymph node metastases, yet optimal management of these recurrences remains unclear. This study evaluates oncological outcomes of patients with BCR after RP and (confirmed or suspected) pelvic lymph node metastases who were treated with PSMA PET/CT-guided salvage whole pelvis radiotherapy (sWPRT) and Androgen Deprivation Therapy (ADT). Materials and methods: This single-centre retrospective analysis included 149 patients undergoing sWPRT and 2-3 years ADT after PSMA PET/CT for BCR following RP ± ePLND (2018-2022). sWPRT was offered to BCR patients with ≤ 6 pelvic PSMA-positive nodes, or to PSMA-negative patients with prior pN1 disease. Outcomes included biochemical progression-free survival (bPFS), metastasis-free survival (MFS), treatment-free survival (TFS), overall survival (OS), and cancer-specific survival (CSS). Multivariate Cox regression identified predictors of biochemical progression. Recurrence locations on PSMA PET/CT were recorded and correlated with radiotherapy fields. Results: After a median 54-month follow-up, 5-year bPFS, MFS, TFS, OS and CSS were; 69.3%, 79.0%, 78.5%, 91.7% and 97.5%. Outcomes did not differ between PSMA-negative and PSMA-positive subgroups. Biochemical progression occurred in 37 patients (25%), with rare in-field recurrences (1/37) and predominantly out-field nodal recurrences (29/37). Higher pre-sWPRT PSA (HR = 3.88, p = 0.021) and longer ADT duration (HR = 0.92, p < 0.001) independently predicted biochemical progression. Conclusion: PSMA PET/CT-guided sWPRT with ADT provides good in-field tumour control and good 5-year oncological outcomes in patients with BCR following RP. PSA prior to sWPRT and ADT duration were significant predictors for bPFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.